Wide Ranks

IBRX

ImmunityBio, Inc.

5.10

Top Statistics
Market Cap 3 B Forward PE -12.14 Revenue Growth 7346.30 %
Current Ratio 2.68 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -13.02 Enterprise / Revenue 606.00 Price To Sales Trailing12 Months 484.70
Profitability
Profit Margins 0.00 % Operating Margins -1314.33 %
Balance Sheet
Total Cash 130 M Total Cash Per Share 0.1870 Total Debt 1 B
Total Debt To Equity Current Ratio 2.68 Book Value Per Share -1.07
All Measures
Short Ratio 576.00 % Message Board Id finmb_303022599 Shares Short Prior Month 51 M
City San Diego Uuid bd5d6a0c-fc2d-3cb7-b719-a9649d726d6f Previous Close 5.12
First Trade Date Epoch Utc 1 B Book Value -1.07 Beta -0.4290
Total Debt 1 B Volume 1 M Fifty Two Week Low 3.10
Total Cash Per Share 0.1870 Total Revenue 7 M Shares Short Previous Month Date 1 B
Target Median Price 8.00 Max Age 86400 Recommendation Mean 1.67
Sand P52 Week Change 0.3133 Operating Margins -1314.33 % Target Mean Price 14.25
Net Income To Common -587793984 Short Percent Of Float 0.3220 Implied Shares Outstanding 696 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 3 M
Average Volume10days 3 M Total Cash 130 M Next Fiscal Year End 1 B
Revenue Per Share 0.0110 Held Percent Insiders 0.7700 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 5.12
Target Low Price 4.75 Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.37
Open 5.20 Free Cashflow -288759872 State CA
Dividend Yield 0.00 % Return On Assets -0.5635 Time Zone Short Name EST
Trailing Eps -0.9000 Day Low 4.96 Address1 3530 John Hopkins Court
Shares Outstanding 696 M Price Hint 2 Target High Price 30.00
Website https://immunitybio.com 52 Week Change 0.3859 Average Volume 5 M
Forward Eps -0.6300 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 221.90 % Is_sp_500 False Regular Market Day High 5.22
Profit Margins 0.00 % Fifty Two Week High 10.53 Day High 5.22
Shares Short 52 M Regular Market Open 5.20 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 606.00 Revenue Growth 7346.30 %
Shares Percent Shares Out 0.0747 Operating Cashflow -421363008 Currency USD
Time Zone Full Name America/New_York Market Cap 3 B Is_nasdaq_100 False
Zip 92121 Quote Type EQUITY Industry Biotechnology
Long Name ImmunityBio, Inc. Regular Market Day Low 4.96 Held Percent Institutions 0.1012
Current Price 5.10 Enterprise To Ebitda -13.02 Financial Currency USD
Current Ratio 2.68 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 165 M
Two Hundred Day Average 5.29 Enterprise Value 4 B Price To Sales Trailing12 Months 484.70
Forward PE -12.14 Regular Market Volume 1 M Ebitda -341304000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.

Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.

Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The company has collaboration agreements with National Cancer Institute.

It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co.

Ltd.

; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.